SlideShare ist ein Scribd-Unternehmen logo
1 von 32
Downloaden Sie, um offline zu lesen
ANTIHYPERTENSIVE DRUGS
Dr. D. K. Brahma
Associate Professor
Department of Pharmacology
NEIGRIHMS, Shillong
INTRODUCTION
Hypertension
Systolic Blood
Pressure (SBP)
Diastolic Blood
Pressure (DBP)
> 140 mmHg > 90 mmHg
****************************************************
CONT…
Types of
Hypertension
Essential Secondary
A disorder of unknown origin affecting the
Blood Pressure regulating mechanisms
Secondary to other disease processes
Environmental
Factors
Stress Na+ Intake Obesity Smoking
****************************************************
TREATMENT – WHY?
 Symptomatic treatment is Mandatory:
1. Damage to the vascular epithelium, paving the path
for atherosclerosis (IHD, CVA)
2. Increased load on heart due to high BP can cause
CHF
3. Nephropathy due to high intra-glomerular pressure
4. Hypertension, even asymptomatic needs treatment
Available groups of major drugs – Diuretics,
ACEIs/ARBs, Beta-blockers, CCBs and others
DIURETICS - MOA
 Drugs causing net loss of Na+ and water in urine
 Mechanism of antihypertensive action:
 Initially: diuresis – depletion of Na+ and body fluid volume
– decrease in cardiac output
 Subsequently , prolong treatment (after 4 - 6 weeks) - Na+
balance and CO is regained by 95%, but BP remains low!
 Due to reduction in total peripheral resistance (TPR) due to
deficit of little amount of Na+ and water (Na+ causes vascular
stiffness)
 Decreased responsiveness to Adr and A-II
 Similar effect is seen with sodium restriction (low sodium diet)
 No postural hypotension – no effect on capacitance
vessels and sympathetic reflexes are not interefered
 Added advantage – potentiate all other
antihypertensives (not DHPs)
THIAZIDE DIURETICS – ADVERSE EFFECTS
 Drawbacks:
 Hypokalaemia – muscle pain and fatigue
 Hyperglycemia: Inhibition of insulin release due to K+
depletion (proinsulin to insulin) – precipitation of diabetes
 Hyperlipidemia: rise in total LDL level and lowering of HDL
– risk of stroke
 Hyperurecaemia: inhibition of urate excretion
 Erectile dysfunction
 Sudden cardiac death – tosades de pointes
(hypokalaemia)
 All the above metabolic side effects – higher doses
(50 – 100 mg per day)
 But, these adverse effects are minimal with low
doses (12.5 to 25 mg) - Average fall in BP is 10 mm
of Hg
 JNC recommendation:
 Preferably, with a potassium sparing diuretic as first choice
in elderly – if fails – another antihypertensive but do not
increase the thiazide dose
DIURETICS – CONTD.
 K+ sparing diuretics:
 Thiazide and K sparing diuretics are combined
therapeutically – DITIDE (triamterene + benzthiazide)
is popular one
 Modified thiazide: indapamide
 Indole derivative and long duration of action (18 Hrs)
– orally 2.5 mg dose
 Reduces the risk of further stroke in stroke patients
 It is a lipid neutral i.e. does not alter blood lipid
concentration, but other adverse effects may remain
 Why Loop diuretics not useful for chronic control?
 Na+ deficient state is temporary, not maintained
round –the-clock and t.p.r not reduced
 Used only in complicated cases – CRF, CHF marked
fluid retention cases
ACE INHIBITORS AND HYPERTENSION
 1st choice of drug in all grades of hypertension
except in bilateral renal stenosis
 Advantages:
 No electrolyte imbalance (no fatigue or weakness) or
postural hypotension
 No hyperuraecemia or deleterious effect on plasma lipid
profile
 Safe in diabetics and asthmatics
 Prevention of secondary hyperaldosteronism and K+
loss
 Reverse the ventricular hypertrophy and increase in
lumen size of vessel
 No rebound hypertension
 Minimal worsening of quality of life – general wellbeing,
sleep and work performance etc.
ACEIS
 Particular advantages:
 Renal blood flow improvement
 Retard diabetic nephropathy
 Regression of LV and vascular hypertrophy -
cardioprotective
 Uses: effective in younger patients (below 55 yrs)
 Patient with diabetes
 Nephropathy
 CHF, angina and MI
 Enalapril/lisinopril – 2.5 mg to 10 mg per day
ANGIOTENSIN RECEPTOR BLOCKERS
 Losartan, candesartan, Valsartan and telmisartan
 Theoretical superiority over ACEIs: free from side effects
 Cough is rare – no interference with bradykinin and other
ACE substrates
 No angioedema, urticaria and taste disturbance
 No effect on heart rate and cardiac reflexes
 Metabolic and prognostic advantages
 Clinical benefit of ARBs over ACEIs (?)
 But, combination therapy: Total suppression of RAS
 A-II generated by non ACE mechanisms – ARBs block
 ACEIs produce bradykinin related vasodilatation – ARBs do
not
 ARBs cause compensatory increase of A-II – ACEIs block
 ARBs indirect activation of AT2 – ACEIs block
 Proved useful in CHF and non-diabetic renal disease –
haemodynamic and symptomatic benefit in CHF
BETA-ADRENERGIC BLOCKERS
 Non selective: Propranolol (others: nadolol, timolol, pindolol and
labetolol) and Cardioselective: Metoprolol (others: atenolol,
acebutalol, esmolol, betaxolol)
 All beta-blockers similar antihypertensive effects:
 Reduction in CO but no change in BP initially but slowly - adaptation
 Other mechanisms – decreased renin release from kidney (beta-1
mediated), decreased central NA ouflow, reduction in g.f.r (non-selective
ones) and reduction in reart rate and CO (ISAs)
 Several contraindications:
 Partial and complete heart block
 COAD and asthma
 Peripheral vascular disease
 Drawbacks: Rebound hypertension
 Raised LDL and lowered HDL and impaired carbohydrate tolerance in
diabetics
 Fatigue, lethargy (low CO?) – decreased work capacity
 Loss of libido – impotence
 Cognitive defects – forgetfulness and nightmares etc.
 Difficult to stop suddenly
 Therefore cardio-selective drugs are preferred now
BETA-ADRENERGIC BLOCKERS –
CONTD.
 Advantages of cardio-selective over non-selective:
 In asthma
 In diabetes mellitus
 In peripheral vascular disease
 Lower incidence of changes in lipid profile
 Overall: beta-blockers as first line of drug
 No postural hypotension
 No salt and water retention
 Low incidence of side effects
 Low cost
 Once a day regime
 Cardioprotective potential
 Preferred:
 In young non-obese patients
 Prevention of sudden cardiac death in post infarction patients and
progression of CHF
 Angina pectoris and post angina patients
 Post MI patients – useful in preventing mortality
 In old persons, carvedilol – vasodilatory action can be given
CALCIUM CHANNEL BLOCKERS
 Verapamil, diltiazem, nifedepine and amlodipine etc.
 Advantages:
 No haemodynamic effect – physical work capacity
 No effect on lipid profile, uric acid level and electrolyte imbalance
 No renal and male sexual function impairment
 Can be given to asthma, angina and PVD patients
 Unlike diuretics no adverse metabolic effects but mild adverse effects like
– dizziness, fatigue etc.
 No sedation or CNS effect
 No adverse fetal effects and can be given in pregnancy
 Minimal effect on quality of life
 Current status:
 Not first line of drug but …?
 However, 1st line - excellent tolerability and high efficacy
 Preferred in elderly and prevents stroke
 CCBs are effective in low Renin hypertension, PVD, asthma and COAD
and pregnancy
 They are next to ACE inhibitors in inhibition of albuminuria and prevention
of diabetic nephropathy
ΑLPHA-ADRENERGIC BLOCKERS
 Non selective alpha-1 blockers are not used in
chronic essential hypertension
(phenoxybenzamine, phentolamine - only used
sometimes as in phaechromocytoma)
 Specific alpha-1 blockers like prazosin, terazosin
and doxazosine are used
 PRAZOSIN is the prototype of the alpha- 1 blockers
 Reduction in t.p.r and mean BP – also reduction in
venomotor tone and pooling of blood – reduction in
CO
 Does not produce tachycardia as presynaptic auto
(alpha-2) receptors are not inhibited –
autoregulation of NA release remains intact
ΑLPHA-ADRENERGIC BLOCKERS –
CONTD.
 Adverse effects:
 Prazosin causes postural hypotension – start 0.5 mg at
bed time with increasing dose and upto 10 mg daily
 Fluid retention in monotherapy
 Headache, dry mouth, weakness, dry mouth, blurred
vision, rash, drowsiness and failure of ejaculation in males
 Current status:
 Several advantages – improvement of carbohydrate
metabolism – diabetics, lowers LDL and increases HDL,
symptomatic improvement in BHP
 But not used as first line agent, used in addition with other
conventional drugs which are failing – diuretic or beta
blocker
 Doses: Available as 0.5 mg, 1 mg, 2.5 mg, 5 mg etc. dose:1-4
mg thrice daily (Minipress/Prazopress)
CENTRALLY ACTING DRUGS
 Clonidine: Imidazoline derivative, partial agonist of
central alpha-2A receptor in CNS – once popular
(moderately potent)
 Frequent side effects– sedation, depression, impotence, salt
and water retention, supersensitivity and rebound
hypertension
 Not frequently used now because of tolerance and withdrawal
hypertension
 Used rarely as 3rd or 4th choice drug – with diuretics
 Methyldopa: a prodrug
 Precursor of Dopamine and NA
 MOA: Converted to alpha methyl noradrenaline which acts on
alpha-2 receptors in brain and causes inhibition of adrenergic
discharge in medulla – fall in t.p.r and fall in BP
 Also inhibits dopadecarboxylase – no NA synthesis
 Various adverse effects – cognitive impairement, postural
hypotension, positive coomb`s test etc. – Not used
therapeutically now except in Hypertension during pregnancy
VASODILATORS - HYDRALAZINE
 Directly acting vasodilator
 MOA: hydralazine molecules combine with receptors in
the endothelium of arterioles – NO release – relaxation
of vascular smooth muscle – fall in BP
 Subsequenly fall in BP – stimulation of adrenergic system
leading to
 Cardiac stimulation producing palpitation and rise in CO even
in IHD and patients – anginal attack
 Tachycardia
 Increased Renin secretion – Na+ retention
 These effects are countered by administration of beta
blockers and diuretics
 However many do not agree to this theory
 Uses: 1) Moderate hypertension when 1st line fails –
with beta-blockers and diuretics 2) Hypertension in
Pregnancy, Dose 25-50 mg OD
SODIUM NITROPRUSSIDE
 Rapidly and consistently acting vasodilator
 Relaxes both resistance and capacitance vessels and
reduces t.p.r and CO (decrease in venous return)
 Unlike hydralazine it produces decrease in cardiac work and
no reflex tachycardia.
 Improves ventricular function in heart failure by reducing
preload
 MOA: 1) RBCs convert nitroprusside to NO – relaxation 2)
by non-enzymatically to NO by glutathione
 Uses: Hypertensive Emergencies, 50 mg is added to 500 ml
of saline/glucose and infused slowly with 0.02 mg/min initially
and later on titrated with response (wrap with black paper)
 Adverse effects: All are due release of cyanides
(thiocyanate) – palpitation, pain abdomen, disorientation,
psychosis, weakness and lactic acidosis.
VASODILATORS - MINOXIDIL (ROGAINE,
REGAINE, MINTOP)
 Powerful vasodilator, mainly 2 major uses – antihypertensive
and alopecia
 Prodrug and converted to an active metabolite which acts by
hyperpolarization of smooth muscles and thereby relaxation of
SM – leading to hydralazine like effects
 Rarely indicated in hypertension especially in life threatening
ones
 More often in alopecia to promote hair growth
 Orally not used any more
 Topically as 2-5% lotion/gel and takes months to get effects
 MOA of hair growth:
 Enhanced microcirculation around hair follicles and also by direct
stimulation of follicles
 Alteration of androgen effect of hair follicles
TREATMENT OF HYPERTENSION
Aim: To prevent mortality and morbidity associated
with persistently raised BP by lowering it to an
acceptable level, with minimum inconvenience to the
patient
TREATMENT OF HYPERTENSION: JNC
7 CLASSIFICATION
BP Systolic Diastolic
Normal >120 <80
Prehypertension 120-139 80-89
Stage1 149-159 90-99
Stage2 >160 >100
1. Age above 55 and 65
in Men and Woman
respectively
2. Family History
3. Smoking
4. DM and Dyslipidemia
5. Hypertension
6. Obesity
7. Microalbuminuria
Categories Risk factors
TREATMENT OF HYPERTENSION – CONTD.
 JNC 7 compelling Indications:
 Heart failure
 Coronary artery disease
 H/o MI
 H/o stroke
 Diabetes
 Chronic Renal failure
TREATMENT OF HYPERTENSION –
CONTD.
TREATMENT OF HYPERTENSION –
GENERAL PRINCIPLES
 Stage I:
 Start with a single most appropriate drug with a low
dose. Preferably start with Thiazides. Others like
beta-blockers, CCBs, ARBs and ACE inhibitors may
also be considered. CCB – in case of elderly and
stroke prevention. If required increase the dose
moderately
 Partial response or no response – add from another
group of drug, but remember it should be a low dose
combination
 If not controlled – change to another low dose
combination
 In case of side effects lower the dose or substitute
with other group
TREATMENT OF HYPERTENSION –
COMBINATION THERAPY
 Stage 2: Start with 2 drug combination – one should
be diuretic
 In clinical practice a large number of patients
require combination therapy – the combination
should be rational and from different patterns of
haemodynamic effects
 Diuretics, CCBs, ACE inhibitors and vasodilators +
beta blockers (blocks renin release)
 Hydralazine /CCBs + beta-blockers (tachycardia
countered)
 ACEIs/ARBs + diuretics in CHF
 Others - ACEIs/ARBs + CCBs or ACEIs/ARBs + beta-
blockers or beta blocker + prazosin
 3 (three) Drug combinations:
CCB+ACE/ARB+diuretic; CCB+Beta blocker+
diuretic; ACEI/ARB+ beta blocker+diuretic
TREATMENT OF HYPERTENSION –
CONTD.
 Never combine:
 Alpha or beta blocker with clonidine - antagonism
 Nifedepine and diuretics synergism (?)
 Hydralazine with DHPs or prazosin – same type of
action
 Diltiazem and verapamil with beta blocker –
bradycardia
 Methyldopa and clonidine
 Hypertension and pregnancy:
 No drug is safe in pregnancy
 Avoid diuretics, propranolol, ACE inhibitors, Sodium
nitroprusside etc
 Safer drugs: Hydralazine, Methyldopa,
cardioselective beta blockers and prazosin
HYPERTENSIVE EMERGENCIES
 Cerebrovascular accident or head injury with high BP
 Left ventricular failure with pulmonary edema due to hypertension
 Hypertensive encephalopathy
 Angina or MI with raised BP
 Acute renal failure with high BP
 Eclampsia
 Pheochromocytoma, cheese reaction and clonidine withdrawal
 Drugs:
 Sodium Nitroprusside (20-300 mcg/min) – dose titration and
monitoring
 GTN (5-20 mcg/min) – cardiac surgery, LVF, MI and angina
 Esmolol (0.5 mg/kg bolus) and 50-200mcg/kg/min - useful in
reducing cardiac work
 Phentolamine – pheochromocytoma, cheese reaction nd clonidine
withdrawal (5-10 mg IV)
ANTIHYPERTENSIVE DRUGS
 Diuretics:
 Thiazides: Hydrochlorothiazide, chlorthalidone
 High ceiling: Furosemide
 K+ sparing: Spironolactone, triamterene and amiloride
MOA: Acts on Kidneys to increase excretion of Na and
H2O – decrease in blood volume – decreased BP
 Angiotensin-converting Enzyme (ACE) inhibitors:
 Captopril, lisinopril., enalapril, ramipril and fosinopril
MOA: Inhibit synthesis of Angiotensin II – decrease in
peripheral resistance and blood volume
 Angiotensin (AT1) blockers:
 Losartan, candesartan, valsartan and telmisartan
MOA: Blocks binding of Angiotensin II to its receptors
ANTIHYPERTENSIVE DRUGS – CONTD.
 Centrally acting: Clonidine, methyldopa
MOA: Act on central α - 2A receptors to decrease sympathetic
outflow – fall in BP
 ß-adrenergic blockers:
 Non selective: Propranolol (others: nadolol, timolol,
pindolol, labetolol)
 Cardioselective: Metoprolol (others: atenolol, esmolol,
betaxolol)
MOA: Bind to beta-adrenergic receptors and blocks the activity
 ß and α – adrenergic blockers:
 Labetolol and carvedilol
 α – adrenergic blockers:
 Prazosin, terazosin, doxazosin, phenoxybenzamine and
phentolamine
MOA: Blocking of alpha adrenergic receptors in smooth muscles
- vasodilatation
ANTIHYPERTENSIVE DRUGS – CONTD.
 Calcium Channel Blockers (CCB):
 Verapamil, diltiazem, nifedipine, felodipine,
amlodipine, nimodipine etc.
MOA: Blocks influx of Ca++ in smooth muscle cells –
relaxation of SMCs – decrease BP
 K+ Channel activators:
 Diazoxide, minoxidil, pinacidil and nicorandil
MOA: Leaking of K+ due to opening – hyper
polarization of SMCs – relaxation of SMCs
 Vasodilators:
 Arteriolar – Hydralazine, minoxidil (also CCBs and K+
channel activators)
 Arterio-venular: Sodium Nitroprusside
WHAT TO KNOW / LEARN ?
 Classification of Antihypertensives
 Antihypertensive mechanisms: Diuretics, ACE
inhibitors, ARBs, Beta-blockers, alpha-blockers,
CCBs
 Common Adverse effects of above groups of Drugs
 Pharmacotherapy of Hypertension
 Pharmacotherapy of hypertensive emergencies
 Central sympatholytics
Antihypertensives - drdhriti

Más contenido relacionado

Was ist angesagt?

Drugs for Congestive Heart Failure
Drugs for Congestive Heart FailureDrugs for Congestive Heart Failure
Drugs for Congestive Heart FailureSMS MEDICAL COLLEGE
 
Antianginal drugs and drugs used in ischaemia - drdhriti
Antianginal drugs and drugs used in ischaemia - drdhritiAntianginal drugs and drugs used in ischaemia - drdhriti
Antianginal drugs and drugs used in ischaemia - drdhritihttp://neigrihms.gov.in/
 
Drugs used in cardiac arrhythmias
Drugs used in cardiac arrhythmiasDrugs used in cardiac arrhythmias
Drugs used in cardiac arrhythmiasPravin Prasad
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugsMahendra Mahi
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugsShikha Popali
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugsNaser Tadvi
 
Antihypertensive drugs naser
Antihypertensive drugs naserAntihypertensive drugs naser
Antihypertensive drugs naserNaser Tadvi
 
Antianginal drug
Antianginal drugAntianginal drug
Antianginal drugpankaj rana
 
Class antiarrhythmic drugs
Class antiarrhythmic drugsClass antiarrhythmic drugs
Class antiarrhythmic drugsRaghu Prasada
 
Calcium Channel Blockers
Calcium Channel Blockers Calcium Channel Blockers
Calcium Channel Blockers Dr Htet
 
Diuretics-Mechanism of action,Diuretic Types and Adverse effects,Drug specifi...
Diuretics-Mechanism of action,Diuretic Types and Adverse effects,Drug specifi...Diuretics-Mechanism of action,Diuretic Types and Adverse effects,Drug specifi...
Diuretics-Mechanism of action,Diuretic Types and Adverse effects,Drug specifi...varinder kumar
 
Antihypertension drugs
Antihypertension drugsAntihypertension drugs
Antihypertension drugspriyanka369989
 

Was ist angesagt? (20)

Angiotensin receptor blockers
Angiotensin receptor blockersAngiotensin receptor blockers
Angiotensin receptor blockers
 
Cardiac Glycosides - drdhriti
Cardiac Glycosides - drdhritiCardiac Glycosides - drdhriti
Cardiac Glycosides - drdhriti
 
Drugs for Congestive Heart Failure
Drugs for Congestive Heart FailureDrugs for Congestive Heart Failure
Drugs for Congestive Heart Failure
 
Antianginal drugs and drugs used in ischaemia - drdhriti
Antianginal drugs and drugs used in ischaemia - drdhritiAntianginal drugs and drugs used in ischaemia - drdhriti
Antianginal drugs and drugs used in ischaemia - drdhriti
 
Drugs used in cardiac arrhythmias
Drugs used in cardiac arrhythmiasDrugs used in cardiac arrhythmias
Drugs used in cardiac arrhythmias
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugs
 
Drugs affecting renin-angiotensin system
Drugs affecting renin-angiotensin systemDrugs affecting renin-angiotensin system
Drugs affecting renin-angiotensin system
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
B blockers
B blockersB blockers
B blockers
 
Antiarrhythmic drugs
Antiarrhythmic drugsAntiarrhythmic drugs
Antiarrhythmic drugs
 
Antihypertensive drugs naser
Antihypertensive drugs naserAntihypertensive drugs naser
Antihypertensive drugs naser
 
Antianginal drug
Antianginal drugAntianginal drug
Antianginal drug
 
Antianginal drugs
Antianginal drugsAntianginal drugs
Antianginal drugs
 
Class antiarrhythmic drugs
Class antiarrhythmic drugsClass antiarrhythmic drugs
Class antiarrhythmic drugs
 
Antiplatelet Drugs
Antiplatelet DrugsAntiplatelet Drugs
Antiplatelet Drugs
 
Calcium Channel Blockers
Calcium Channel Blockers Calcium Channel Blockers
Calcium Channel Blockers
 
Diuretics-Mechanism of action,Diuretic Types and Adverse effects,Drug specifi...
Diuretics-Mechanism of action,Diuretic Types and Adverse effects,Drug specifi...Diuretics-Mechanism of action,Diuretic Types and Adverse effects,Drug specifi...
Diuretics-Mechanism of action,Diuretic Types and Adverse effects,Drug specifi...
 
Sulfonylureas
SulfonylureasSulfonylureas
Sulfonylureas
 
Drugs for heart failure
Drugs for heart failureDrugs for heart failure
Drugs for heart failure
 
Antihypertension drugs
Antihypertension drugsAntihypertension drugs
Antihypertension drugs
 

Andere mochten auch

Anti Hypertensive Drugs
Anti Hypertensive DrugsAnti Hypertensive Drugs
Anti Hypertensive Drugsmohammed sediq
 
Antihypertensives
AntihypertensivesAntihypertensives
Antihypertensivesraj kumar
 
Antiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohnaAntiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohnaDr Roohana Hasan
 
Recent advances in treatment of Hypertension -- Drugs inhibiting RAAS, Diuret...
Recent advances in treatment of Hypertension -- Drugs inhibiting RAAS, Diuret...Recent advances in treatment of Hypertension -- Drugs inhibiting RAAS, Diuret...
Recent advances in treatment of Hypertension -- Drugs inhibiting RAAS, Diuret...Deepthivagge
 
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...Dr. Ravi Sankar
 
Drugs used in hypertension
Drugs used in hypertensionDrugs used in hypertension
Drugs used in hypertensionSara Memon
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugspavelbd
 
Teratogenicity oncogenicity mutagenicity and allergenicity
Teratogenicity oncogenicity mutagenicity and allergenicityTeratogenicity oncogenicity mutagenicity and allergenicity
Teratogenicity oncogenicity mutagenicity and allergenicityKoppala RVS Chaitanya
 
Pharmacology of Proteins and peptides
Pharmacology of Proteins and peptidesPharmacology of Proteins and peptides
Pharmacology of Proteins and peptidesKoppala RVS Chaitanya
 

Andere mochten auch (13)

Anti Hypertensive Drugs
Anti Hypertensive DrugsAnti Hypertensive Drugs
Anti Hypertensive Drugs
 
Antihypertensives
AntihypertensivesAntihypertensives
Antihypertensives
 
Antiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohnaAntiemetics and prokinetics by dr.roohna
Antiemetics and prokinetics by dr.roohna
 
Recent advances in treatment of Hypertension -- Drugs inhibiting RAAS, Diuret...
Recent advances in treatment of Hypertension -- Drugs inhibiting RAAS, Diuret...Recent advances in treatment of Hypertension -- Drugs inhibiting RAAS, Diuret...
Recent advances in treatment of Hypertension -- Drugs inhibiting RAAS, Diuret...
 
Screening of anti-emetic drugs
Screening of anti-emetic drugsScreening of anti-emetic drugs
Screening of anti-emetic drugs
 
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
ANTI HYPERTENSIVE AGENTS [MEDICINAL CHEMISTRY] BY P.RAVISANKAR, HYPERTENSION,...
 
Drugs used in hypertension
Drugs used in hypertensionDrugs used in hypertension
Drugs used in hypertension
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Teratogenicity oncogenicity mutagenicity and allergenicity
Teratogenicity oncogenicity mutagenicity and allergenicityTeratogenicity oncogenicity mutagenicity and allergenicity
Teratogenicity oncogenicity mutagenicity and allergenicity
 
Emetics and Anti emetics
Emetics and Anti emeticsEmetics and Anti emetics
Emetics and Anti emetics
 
peptic ulcer
 peptic ulcer  peptic ulcer
peptic ulcer
 
Pharmacology of Proteins and peptides
Pharmacology of Proteins and peptidesPharmacology of Proteins and peptides
Pharmacology of Proteins and peptides
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 

Ähnlich wie Antihypertensives - drdhriti

pharmacotherapy of hypertension
pharmacotherapy of hypertensionpharmacotherapy of hypertension
pharmacotherapy of hypertensionAdil Shah
 
ANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUGANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUGAkshit Naveria
 
Antihypertensives and anesthetic implications - Dr. Vaibhav
Antihypertensives and anesthetic implications  - Dr. VaibhavAntihypertensives and anesthetic implications  - Dr. Vaibhav
Antihypertensives and anesthetic implications - Dr. VaibhavVaibhav Tulsyan
 
Antihypertensive drug part 1
Antihypertensive drug part 1 Antihypertensive drug part 1
Antihypertensive drug part 1 dr nainika sharma
 
Drugs used in hypertension
Drugs used in hypertensionDrugs used in hypertension
Drugs used in hypertensionGoutam Mallik
 
anti hypertensive copy.pptx
anti hypertensive copy.pptxanti hypertensive copy.pptx
anti hypertensive copy.pptxKhaledEwais1
 
Class antihypertensives
Class antihypertensivesClass antihypertensives
Class antihypertensivesRaghu Prasada
 
Antihypertension pharmacology
Antihypertension pharmacologyAntihypertension pharmacology
Antihypertension pharmacology9ikram9
 
hypertension final (1).ppt
hypertension final (1).ppthypertension final (1).ppt
hypertension final (1).pptJhansi Uppu
 
Antihypertensive agents
Antihypertensive agentsAntihypertensive agents
Antihypertensive agentsSujit Karpe
 
Pharmacotherapy of heart failure
Pharmacotherapy of heart failurePharmacotherapy of heart failure
Pharmacotherapy of heart failureDr. Shivesh Gupta
 
08 Antihypertensives Upd
08 Antihypertensives Upd08 Antihypertensives Upd
08 Antihypertensives UpdNurse Uragon
 
Cardiovascular+pharmacology+drug+therapy+of+hypertension
Cardiovascular+pharmacology+drug+therapy+of+hypertensionCardiovascular+pharmacology+drug+therapy+of+hypertension
Cardiovascular+pharmacology+drug+therapy+of+hypertensionDr.Ebrahim Eltanbouly
 
Essential hypertension management and treatment
Essential hypertension management  and treatmentEssential hypertension management  and treatment
Essential hypertension management and treatmentFabio Grubba
 

Ähnlich wie Antihypertensives - drdhriti (20)

AntiHypertensive Drugs
AntiHypertensive DrugsAntiHypertensive Drugs
AntiHypertensive Drugs
 
worlb bank
worlb bankworlb bank
worlb bank
 
pharmacotherapy of hypertension
pharmacotherapy of hypertensionpharmacotherapy of hypertension
pharmacotherapy of hypertension
 
ANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUGANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUG
 
Antihypertensives and anesthetic implications - Dr. Vaibhav
Antihypertensives and anesthetic implications  - Dr. VaibhavAntihypertensives and anesthetic implications  - Dr. Vaibhav
Antihypertensives and anesthetic implications - Dr. Vaibhav
 
Antihypertensive drug part 1
Antihypertensive drug part 1 Antihypertensive drug part 1
Antihypertensive drug part 1
 
Drugs used in hypertension
Drugs used in hypertensionDrugs used in hypertension
Drugs used in hypertension
 
anti hypertensive copy.pptx
anti hypertensive copy.pptxanti hypertensive copy.pptx
anti hypertensive copy.pptx
 
Hypertension drug therapy
Hypertension   drug therapyHypertension   drug therapy
Hypertension drug therapy
 
Class antihypertensives
Class antihypertensivesClass antihypertensives
Class antihypertensives
 
Cardiodrugs
CardiodrugsCardiodrugs
Cardiodrugs
 
Antihypertension pharmacology
Antihypertension pharmacologyAntihypertension pharmacology
Antihypertension pharmacology
 
hypertension final (1).ppt
hypertension final (1).ppthypertension final (1).ppt
hypertension final (1).ppt
 
Antihypertensive agents
Antihypertensive agentsAntihypertensive agents
Antihypertensive agents
 
Pharmacotherapy of heart failure
Pharmacotherapy of heart failurePharmacotherapy of heart failure
Pharmacotherapy of heart failure
 
08 Antihypertensives Upd
08 Antihypertensives Upd08 Antihypertensives Upd
08 Antihypertensives Upd
 
Cardiovascular+pharmacology+drug+therapy+of+hypertension
Cardiovascular+pharmacology+drug+therapy+of+hypertensionCardiovascular+pharmacology+drug+therapy+of+hypertension
Cardiovascular+pharmacology+drug+therapy+of+hypertension
 
Essential hypertension management and treatment
Essential hypertension management  and treatmentEssential hypertension management  and treatment
Essential hypertension management and treatment
 
Ihd
IhdIhd
Ihd
 
Ihd
IhdIhd
Ihd
 

Mehr von http://neigrihms.gov.in/

Excretion of drugs and kinetics of elimination
Excretion of drugs and kinetics of eliminationExcretion of drugs and kinetics of elimination
Excretion of drugs and kinetics of eliminationhttp://neigrihms.gov.in/
 
Antimanic drugs and mood stabilizing agents
Antimanic drugs and mood stabilizing agentsAntimanic drugs and mood stabilizing agents
Antimanic drugs and mood stabilizing agentshttp://neigrihms.gov.in/
 
Cholinergic Pharmacology and Cholinergic Drugs 2017
Cholinergic Pharmacology and Cholinergic Drugs 2017Cholinergic Pharmacology and Cholinergic Drugs 2017
Cholinergic Pharmacology and Cholinergic Drugs 2017http://neigrihms.gov.in/
 

Mehr von http://neigrihms.gov.in/ (20)

Ectoparasiticides
EctoparasiticidesEctoparasiticides
Ectoparasiticides
 
Antimalarial Drugs Pharmacology
Antimalarial Drugs PharmacologyAntimalarial Drugs Pharmacology
Antimalarial Drugs Pharmacology
 
Fluoroquinolones
Fluoroquinolones Fluoroquinolones
Fluoroquinolones
 
Betalactum antibiotics
Betalactum antibioticsBetalactum antibiotics
Betalactum antibiotics
 
Excretion of drugs and kinetics of elimination
Excretion of drugs and kinetics of eliminationExcretion of drugs and kinetics of elimination
Excretion of drugs and kinetics of elimination
 
Pharmacology of Antitubercular Drugs
 Pharmacology of Antitubercular Drugs  Pharmacology of Antitubercular Drugs
Pharmacology of Antitubercular Drugs
 
Drugs used in glaucoma
Drugs used in glaucomaDrugs used in glaucoma
Drugs used in glaucoma
 
NSAIDS
NSAIDSNSAIDS
NSAIDS
 
Antimanic drugs and mood stabilizing agents
Antimanic drugs and mood stabilizing agentsAntimanic drugs and mood stabilizing agents
Antimanic drugs and mood stabilizing agents
 
Polypeptide antibiotics
Polypeptide antibioticsPolypeptide antibiotics
Polypeptide antibiotics
 
Medications in the elderly
Medications in the elderlyMedications in the elderly
Medications in the elderly
 
Pharmacotherapy of shock
Pharmacotherapy of shockPharmacotherapy of shock
Pharmacotherapy of shock
 
Factors modifying drug action
Factors modifying drug actionFactors modifying drug action
Factors modifying drug action
 
Oral hypoglycaemic drugs
Oral hypoglycaemic drugsOral hypoglycaemic drugs
Oral hypoglycaemic drugs
 
Insulin pharmacology
Insulin pharmacologyInsulin pharmacology
Insulin pharmacology
 
CNS stimulants and cognition enhancers
CNS stimulants and cognition enhancersCNS stimulants and cognition enhancers
CNS stimulants and cognition enhancers
 
Sedative hypnotics.ppt - dr dhriti
Sedative hypnotics.ppt - dr dhriti Sedative hypnotics.ppt - dr dhriti
Sedative hypnotics.ppt - dr dhriti
 
Antirheumatoid drugs
Antirheumatoid drugsAntirheumatoid drugs
Antirheumatoid drugs
 
Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)
 
Cholinergic Pharmacology and Cholinergic Drugs 2017
Cholinergic Pharmacology and Cholinergic Drugs 2017Cholinergic Pharmacology and Cholinergic Drugs 2017
Cholinergic Pharmacology and Cholinergic Drugs 2017
 

Último

ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxsiddharthroy26587
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUKanhu Charan
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdfHongBiThi1
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...JakeMatthews12
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhanthesalberry
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisAshishMaletha2
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxSizan Thapa
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHUKanhu Charan
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptxushakiranmai4
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 

Último (20)

ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
 
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
 
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN              .pdfSGK VIÊM KHỚP DẠNG THẤP YHN              .pdf
SGK VIÊM KHỚP DẠNG THẤP YHN .pdf
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...The Art and the Science of UK General Practice A historical review and timeli...
The Art and the Science of UK General Practice A historical review and timeli...
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhan
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
Basic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth AnalysisBasic of Thyroid Hormone:- An In-depth Analysis
Basic of Thyroid Hormone:- An In-depth Analysis
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptx
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptx
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 

Antihypertensives - drdhriti

  • 1. ANTIHYPERTENSIVE DRUGS Dr. D. K. Brahma Associate Professor Department of Pharmacology NEIGRIHMS, Shillong
  • 2. INTRODUCTION Hypertension Systolic Blood Pressure (SBP) Diastolic Blood Pressure (DBP) > 140 mmHg > 90 mmHg ****************************************************
  • 3. CONT… Types of Hypertension Essential Secondary A disorder of unknown origin affecting the Blood Pressure regulating mechanisms Secondary to other disease processes Environmental Factors Stress Na+ Intake Obesity Smoking ****************************************************
  • 4. TREATMENT – WHY?  Symptomatic treatment is Mandatory: 1. Damage to the vascular epithelium, paving the path for atherosclerosis (IHD, CVA) 2. Increased load on heart due to high BP can cause CHF 3. Nephropathy due to high intra-glomerular pressure 4. Hypertension, even asymptomatic needs treatment Available groups of major drugs – Diuretics, ACEIs/ARBs, Beta-blockers, CCBs and others
  • 5. DIURETICS - MOA  Drugs causing net loss of Na+ and water in urine  Mechanism of antihypertensive action:  Initially: diuresis – depletion of Na+ and body fluid volume – decrease in cardiac output  Subsequently , prolong treatment (after 4 - 6 weeks) - Na+ balance and CO is regained by 95%, but BP remains low!  Due to reduction in total peripheral resistance (TPR) due to deficit of little amount of Na+ and water (Na+ causes vascular stiffness)  Decreased responsiveness to Adr and A-II  Similar effect is seen with sodium restriction (low sodium diet)  No postural hypotension – no effect on capacitance vessels and sympathetic reflexes are not interefered  Added advantage – potentiate all other antihypertensives (not DHPs)
  • 6. THIAZIDE DIURETICS – ADVERSE EFFECTS  Drawbacks:  Hypokalaemia – muscle pain and fatigue  Hyperglycemia: Inhibition of insulin release due to K+ depletion (proinsulin to insulin) – precipitation of diabetes  Hyperlipidemia: rise in total LDL level and lowering of HDL – risk of stroke  Hyperurecaemia: inhibition of urate excretion  Erectile dysfunction  Sudden cardiac death – tosades de pointes (hypokalaemia)  All the above metabolic side effects – higher doses (50 – 100 mg per day)  But, these adverse effects are minimal with low doses (12.5 to 25 mg) - Average fall in BP is 10 mm of Hg  JNC recommendation:  Preferably, with a potassium sparing diuretic as first choice in elderly – if fails – another antihypertensive but do not increase the thiazide dose
  • 7. DIURETICS – CONTD.  K+ sparing diuretics:  Thiazide and K sparing diuretics are combined therapeutically – DITIDE (triamterene + benzthiazide) is popular one  Modified thiazide: indapamide  Indole derivative and long duration of action (18 Hrs) – orally 2.5 mg dose  Reduces the risk of further stroke in stroke patients  It is a lipid neutral i.e. does not alter blood lipid concentration, but other adverse effects may remain  Why Loop diuretics not useful for chronic control?  Na+ deficient state is temporary, not maintained round –the-clock and t.p.r not reduced  Used only in complicated cases – CRF, CHF marked fluid retention cases
  • 8. ACE INHIBITORS AND HYPERTENSION  1st choice of drug in all grades of hypertension except in bilateral renal stenosis  Advantages:  No electrolyte imbalance (no fatigue or weakness) or postural hypotension  No hyperuraecemia or deleterious effect on plasma lipid profile  Safe in diabetics and asthmatics  Prevention of secondary hyperaldosteronism and K+ loss  Reverse the ventricular hypertrophy and increase in lumen size of vessel  No rebound hypertension  Minimal worsening of quality of life – general wellbeing, sleep and work performance etc.
  • 9. ACEIS  Particular advantages:  Renal blood flow improvement  Retard diabetic nephropathy  Regression of LV and vascular hypertrophy - cardioprotective  Uses: effective in younger patients (below 55 yrs)  Patient with diabetes  Nephropathy  CHF, angina and MI  Enalapril/lisinopril – 2.5 mg to 10 mg per day
  • 10. ANGIOTENSIN RECEPTOR BLOCKERS  Losartan, candesartan, Valsartan and telmisartan  Theoretical superiority over ACEIs: free from side effects  Cough is rare – no interference with bradykinin and other ACE substrates  No angioedema, urticaria and taste disturbance  No effect on heart rate and cardiac reflexes  Metabolic and prognostic advantages  Clinical benefit of ARBs over ACEIs (?)  But, combination therapy: Total suppression of RAS  A-II generated by non ACE mechanisms – ARBs block  ACEIs produce bradykinin related vasodilatation – ARBs do not  ARBs cause compensatory increase of A-II – ACEIs block  ARBs indirect activation of AT2 – ACEIs block  Proved useful in CHF and non-diabetic renal disease – haemodynamic and symptomatic benefit in CHF
  • 11. BETA-ADRENERGIC BLOCKERS  Non selective: Propranolol (others: nadolol, timolol, pindolol and labetolol) and Cardioselective: Metoprolol (others: atenolol, acebutalol, esmolol, betaxolol)  All beta-blockers similar antihypertensive effects:  Reduction in CO but no change in BP initially but slowly - adaptation  Other mechanisms – decreased renin release from kidney (beta-1 mediated), decreased central NA ouflow, reduction in g.f.r (non-selective ones) and reduction in reart rate and CO (ISAs)  Several contraindications:  Partial and complete heart block  COAD and asthma  Peripheral vascular disease  Drawbacks: Rebound hypertension  Raised LDL and lowered HDL and impaired carbohydrate tolerance in diabetics  Fatigue, lethargy (low CO?) – decreased work capacity  Loss of libido – impotence  Cognitive defects – forgetfulness and nightmares etc.  Difficult to stop suddenly  Therefore cardio-selective drugs are preferred now
  • 12. BETA-ADRENERGIC BLOCKERS – CONTD.  Advantages of cardio-selective over non-selective:  In asthma  In diabetes mellitus  In peripheral vascular disease  Lower incidence of changes in lipid profile  Overall: beta-blockers as first line of drug  No postural hypotension  No salt and water retention  Low incidence of side effects  Low cost  Once a day regime  Cardioprotective potential  Preferred:  In young non-obese patients  Prevention of sudden cardiac death in post infarction patients and progression of CHF  Angina pectoris and post angina patients  Post MI patients – useful in preventing mortality  In old persons, carvedilol – vasodilatory action can be given
  • 13. CALCIUM CHANNEL BLOCKERS  Verapamil, diltiazem, nifedepine and amlodipine etc.  Advantages:  No haemodynamic effect – physical work capacity  No effect on lipid profile, uric acid level and electrolyte imbalance  No renal and male sexual function impairment  Can be given to asthma, angina and PVD patients  Unlike diuretics no adverse metabolic effects but mild adverse effects like – dizziness, fatigue etc.  No sedation or CNS effect  No adverse fetal effects and can be given in pregnancy  Minimal effect on quality of life  Current status:  Not first line of drug but …?  However, 1st line - excellent tolerability and high efficacy  Preferred in elderly and prevents stroke  CCBs are effective in low Renin hypertension, PVD, asthma and COAD and pregnancy  They are next to ACE inhibitors in inhibition of albuminuria and prevention of diabetic nephropathy
  • 14. ΑLPHA-ADRENERGIC BLOCKERS  Non selective alpha-1 blockers are not used in chronic essential hypertension (phenoxybenzamine, phentolamine - only used sometimes as in phaechromocytoma)  Specific alpha-1 blockers like prazosin, terazosin and doxazosine are used  PRAZOSIN is the prototype of the alpha- 1 blockers  Reduction in t.p.r and mean BP – also reduction in venomotor tone and pooling of blood – reduction in CO  Does not produce tachycardia as presynaptic auto (alpha-2) receptors are not inhibited – autoregulation of NA release remains intact
  • 15. ΑLPHA-ADRENERGIC BLOCKERS – CONTD.  Adverse effects:  Prazosin causes postural hypotension – start 0.5 mg at bed time with increasing dose and upto 10 mg daily  Fluid retention in monotherapy  Headache, dry mouth, weakness, dry mouth, blurred vision, rash, drowsiness and failure of ejaculation in males  Current status:  Several advantages – improvement of carbohydrate metabolism – diabetics, lowers LDL and increases HDL, symptomatic improvement in BHP  But not used as first line agent, used in addition with other conventional drugs which are failing – diuretic or beta blocker  Doses: Available as 0.5 mg, 1 mg, 2.5 mg, 5 mg etc. dose:1-4 mg thrice daily (Minipress/Prazopress)
  • 16. CENTRALLY ACTING DRUGS  Clonidine: Imidazoline derivative, partial agonist of central alpha-2A receptor in CNS – once popular (moderately potent)  Frequent side effects– sedation, depression, impotence, salt and water retention, supersensitivity and rebound hypertension  Not frequently used now because of tolerance and withdrawal hypertension  Used rarely as 3rd or 4th choice drug – with diuretics  Methyldopa: a prodrug  Precursor of Dopamine and NA  MOA: Converted to alpha methyl noradrenaline which acts on alpha-2 receptors in brain and causes inhibition of adrenergic discharge in medulla – fall in t.p.r and fall in BP  Also inhibits dopadecarboxylase – no NA synthesis  Various adverse effects – cognitive impairement, postural hypotension, positive coomb`s test etc. – Not used therapeutically now except in Hypertension during pregnancy
  • 17. VASODILATORS - HYDRALAZINE  Directly acting vasodilator  MOA: hydralazine molecules combine with receptors in the endothelium of arterioles – NO release – relaxation of vascular smooth muscle – fall in BP  Subsequenly fall in BP – stimulation of adrenergic system leading to  Cardiac stimulation producing palpitation and rise in CO even in IHD and patients – anginal attack  Tachycardia  Increased Renin secretion – Na+ retention  These effects are countered by administration of beta blockers and diuretics  However many do not agree to this theory  Uses: 1) Moderate hypertension when 1st line fails – with beta-blockers and diuretics 2) Hypertension in Pregnancy, Dose 25-50 mg OD
  • 18. SODIUM NITROPRUSSIDE  Rapidly and consistently acting vasodilator  Relaxes both resistance and capacitance vessels and reduces t.p.r and CO (decrease in venous return)  Unlike hydralazine it produces decrease in cardiac work and no reflex tachycardia.  Improves ventricular function in heart failure by reducing preload  MOA: 1) RBCs convert nitroprusside to NO – relaxation 2) by non-enzymatically to NO by glutathione  Uses: Hypertensive Emergencies, 50 mg is added to 500 ml of saline/glucose and infused slowly with 0.02 mg/min initially and later on titrated with response (wrap with black paper)  Adverse effects: All are due release of cyanides (thiocyanate) – palpitation, pain abdomen, disorientation, psychosis, weakness and lactic acidosis.
  • 19. VASODILATORS - MINOXIDIL (ROGAINE, REGAINE, MINTOP)  Powerful vasodilator, mainly 2 major uses – antihypertensive and alopecia  Prodrug and converted to an active metabolite which acts by hyperpolarization of smooth muscles and thereby relaxation of SM – leading to hydralazine like effects  Rarely indicated in hypertension especially in life threatening ones  More often in alopecia to promote hair growth  Orally not used any more  Topically as 2-5% lotion/gel and takes months to get effects  MOA of hair growth:  Enhanced microcirculation around hair follicles and also by direct stimulation of follicles  Alteration of androgen effect of hair follicles
  • 20. TREATMENT OF HYPERTENSION Aim: To prevent mortality and morbidity associated with persistently raised BP by lowering it to an acceptable level, with minimum inconvenience to the patient
  • 21. TREATMENT OF HYPERTENSION: JNC 7 CLASSIFICATION BP Systolic Diastolic Normal >120 <80 Prehypertension 120-139 80-89 Stage1 149-159 90-99 Stage2 >160 >100 1. Age above 55 and 65 in Men and Woman respectively 2. Family History 3. Smoking 4. DM and Dyslipidemia 5. Hypertension 6. Obesity 7. Microalbuminuria Categories Risk factors
  • 22. TREATMENT OF HYPERTENSION – CONTD.  JNC 7 compelling Indications:  Heart failure  Coronary artery disease  H/o MI  H/o stroke  Diabetes  Chronic Renal failure
  • 24. TREATMENT OF HYPERTENSION – GENERAL PRINCIPLES  Stage I:  Start with a single most appropriate drug with a low dose. Preferably start with Thiazides. Others like beta-blockers, CCBs, ARBs and ACE inhibitors may also be considered. CCB – in case of elderly and stroke prevention. If required increase the dose moderately  Partial response or no response – add from another group of drug, but remember it should be a low dose combination  If not controlled – change to another low dose combination  In case of side effects lower the dose or substitute with other group
  • 25. TREATMENT OF HYPERTENSION – COMBINATION THERAPY  Stage 2: Start with 2 drug combination – one should be diuretic  In clinical practice a large number of patients require combination therapy – the combination should be rational and from different patterns of haemodynamic effects  Diuretics, CCBs, ACE inhibitors and vasodilators + beta blockers (blocks renin release)  Hydralazine /CCBs + beta-blockers (tachycardia countered)  ACEIs/ARBs + diuretics in CHF  Others - ACEIs/ARBs + CCBs or ACEIs/ARBs + beta- blockers or beta blocker + prazosin  3 (three) Drug combinations: CCB+ACE/ARB+diuretic; CCB+Beta blocker+ diuretic; ACEI/ARB+ beta blocker+diuretic
  • 26. TREATMENT OF HYPERTENSION – CONTD.  Never combine:  Alpha or beta blocker with clonidine - antagonism  Nifedepine and diuretics synergism (?)  Hydralazine with DHPs or prazosin – same type of action  Diltiazem and verapamil with beta blocker – bradycardia  Methyldopa and clonidine  Hypertension and pregnancy:  No drug is safe in pregnancy  Avoid diuretics, propranolol, ACE inhibitors, Sodium nitroprusside etc  Safer drugs: Hydralazine, Methyldopa, cardioselective beta blockers and prazosin
  • 27. HYPERTENSIVE EMERGENCIES  Cerebrovascular accident or head injury with high BP  Left ventricular failure with pulmonary edema due to hypertension  Hypertensive encephalopathy  Angina or MI with raised BP  Acute renal failure with high BP  Eclampsia  Pheochromocytoma, cheese reaction and clonidine withdrawal  Drugs:  Sodium Nitroprusside (20-300 mcg/min) – dose titration and monitoring  GTN (5-20 mcg/min) – cardiac surgery, LVF, MI and angina  Esmolol (0.5 mg/kg bolus) and 50-200mcg/kg/min - useful in reducing cardiac work  Phentolamine – pheochromocytoma, cheese reaction nd clonidine withdrawal (5-10 mg IV)
  • 28. ANTIHYPERTENSIVE DRUGS  Diuretics:  Thiazides: Hydrochlorothiazide, chlorthalidone  High ceiling: Furosemide  K+ sparing: Spironolactone, triamterene and amiloride MOA: Acts on Kidneys to increase excretion of Na and H2O – decrease in blood volume – decreased BP  Angiotensin-converting Enzyme (ACE) inhibitors:  Captopril, lisinopril., enalapril, ramipril and fosinopril MOA: Inhibit synthesis of Angiotensin II – decrease in peripheral resistance and blood volume  Angiotensin (AT1) blockers:  Losartan, candesartan, valsartan and telmisartan MOA: Blocks binding of Angiotensin II to its receptors
  • 29. ANTIHYPERTENSIVE DRUGS – CONTD.  Centrally acting: Clonidine, methyldopa MOA: Act on central α - 2A receptors to decrease sympathetic outflow – fall in BP  ß-adrenergic blockers:  Non selective: Propranolol (others: nadolol, timolol, pindolol, labetolol)  Cardioselective: Metoprolol (others: atenolol, esmolol, betaxolol) MOA: Bind to beta-adrenergic receptors and blocks the activity  ß and α – adrenergic blockers:  Labetolol and carvedilol  α – adrenergic blockers:  Prazosin, terazosin, doxazosin, phenoxybenzamine and phentolamine MOA: Blocking of alpha adrenergic receptors in smooth muscles - vasodilatation
  • 30. ANTIHYPERTENSIVE DRUGS – CONTD.  Calcium Channel Blockers (CCB):  Verapamil, diltiazem, nifedipine, felodipine, amlodipine, nimodipine etc. MOA: Blocks influx of Ca++ in smooth muscle cells – relaxation of SMCs – decrease BP  K+ Channel activators:  Diazoxide, minoxidil, pinacidil and nicorandil MOA: Leaking of K+ due to opening – hyper polarization of SMCs – relaxation of SMCs  Vasodilators:  Arteriolar – Hydralazine, minoxidil (also CCBs and K+ channel activators)  Arterio-venular: Sodium Nitroprusside
  • 31. WHAT TO KNOW / LEARN ?  Classification of Antihypertensives  Antihypertensive mechanisms: Diuretics, ACE inhibitors, ARBs, Beta-blockers, alpha-blockers, CCBs  Common Adverse effects of above groups of Drugs  Pharmacotherapy of Hypertension  Pharmacotherapy of hypertensive emergencies  Central sympatholytics

Hinweis der Redaktion

  1. Baroreflexes are responsible for minute to minute regulation of BP. Central sympathetic neurones in vasomotor area are tonically active. When there is stretch in the vessel wall brought about by rise in pressure, baroreceptor stimulation occurs and inhibits sympathetic discharge. On the other hand reduction in stretch, increases baroreceptor activity. Therefore, there will be increase in PVR (constriction of arterioles), and increase in CO (increase in venous return due to constriction of capacitance venules and direct stimulation of heart – thereby restoring normal blood pressure. Acts in vasodilators and shock.
  2. Inhibition of insulin release due to K+ depletion – ppt of diabetes a type of ventricular tachycardia with a spiral-like appearance (&amp;quot;twisting of the points&amp;quot;) and complexes that at first look positive and then negative on an electrocardiogram. It is precipitated by a long Q-T interval, which often is induced by drugs (quinidine, procainamide, or disopyramide) but which may be the result of hypokalemia, hypomagnesemia, or profound bradycardia. The first line of treatment is IV magnesium sulfate, as well as defibrillation if the patient is unstable
  3. RAS is important in case of normal physiological maintainance of homeostasis. RAS plays an important role in development of hypertension. In most of the cases of hypertension PRA is seen to be raised. The long term effects of persistenly active PRA leads to cardiac hypertrophy (ventricular) and remodelling and also coronary artery hypertrophy and remodelling. Therefore by blocking of the hypertension can be controlled by blocking of ACE practically in most of the hypertensive cases.
  4. ACE inhibitors have many indications apart from the hypertension which will be talked when particular diseases are talked, For you now you have to remember is that what are the they are the first line of agent now in most of the cases of hypertension specially in young person and persons with ventricular hypertrophy. In practice they are used as first line of agent as monotherapy or in combination with diuretics and beta-blockers. The advantages of ACEIs are
  5. itogen-activated protein (MAP) kinases ( EC   2.7.11.24 ) are  serine/threonine-specific protein kinases  that respond to extracellular stimuli ( mitogens ,  osmotic stress ,  heat shock and  proinflammatory cytokines ) and regulate various cellular activities, such as  gene expression ,  mitosis ,  differentiation , proliferation, and cell survival/ apoptosis . [1